Clinical Advances in Management of Urologic Diseases

Dear Colleagues,

The management of urologic malignancies is undergoing rapid transformation, driven by advances in imaging, molecular profiling, surgical techniques, and systemic therapy. This Special Issue, “Clinical Advances in Management of Urologic Diseases”, brings together cutting-edge research and authoritative reviews that are focused on two areas of the highest global impact: prostate cancer and bladder cancer.

In prostate cancer, multiparametric MRI pathways and targeted biopsies have reshaped early detection and risk stratification, while PSMA-based imaging is redefining staging and disease localization. Contemporary management spans precision focal therapies, refinements in radical prostatectomy and radiotherapy, and optimized systemic strategies across the disease continuum—from hormone-sensitive to castration-resistant states. Emerging directions include molecularly guided care (e.g., homologous-recombination repair–informed treatment), radioligand therapy, minimal-residual-disease assessment via liquid biopsy, and survivorship models that prioritize urinary, sexual, and overall quality-of-life outcomes.

In bladder cancer, innovations are improving both diagnosis and treatment across non-muscle-invasive and muscle-invasive disease. Enhanced cystoscopy and urinary biomarkers aim to reduce under- or overtreatment, while bladder-preserving trimodality approaches offer alternatives to cystectomy for selected patients. Perioperative systemic therapy continues to evolve alongside immuno-oncology and antibody–drug conjugates in advanced settings. Molecular subtyping and variant histology are informing therapeutic choices, and advanced cross-sectional and nuclear imaging including FDG-PET/CT are refining nodal and distant staging to guide timely multimodal care.

We particularly welcome submissions that do the following:

• Integrate imaging, genomics, and pathology to enable personalized treatment;
• Evaluate novel systemic therapies, combinations, sequencing, and biomarkers of response/resistance;
• Advance surgical and radiotherapy techniques, perioperative pathways, and functional outcomes;
• Explore bladder-preserving strategies, BCG-unresponsive disease, and management of variant histology;
• Apply AI/radiomics, liquid biopsy, and real-world evidence to improve decision-making and equity of care.

As Guest Editors, we invite original research and state-of-the-art reviews that move the field toward more accurate staging, smarter treatment selection, and better patient-reported outcomes. Together, these contributions will chart a pragmatic, patient-centered roadmap for the next era in urologic oncology.

Dr. Francesco Pio Bizzarri
Dr. Calogero Casà
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• prostate cancer
• bladder cancer
• kidney cancer
• uro-oncology
• radiotherapy